奧特佳(002239.SZ):江蘇帝奧所持5504萬股將被司法拍賣
格隆匯12月11日丨奧特佳(002239.SZ)公佈,公司今日獲悉,公司股東江蘇帝奧控股集團股份有限公司(以下簡稱江蘇帝奧)所持有的公司5504萬股股份將被司法拍賣。
南京市中級人民法院將於2019年12月12日10時至2019年12月13日10時止(延時的除外)在南京市中級人民法院淘寶網司法拍賣網絡平台上(,户名:南京市中級人民法院)對江蘇帝奧持有的部分股權進行公開拍賣。
起拍價為9868.672萬元(為拍賣當日前三個工作日的前十個交易日收盤價均價乘以總股數,即2019年12月9日前十個交易日收盤均價乘以5504萬股),保證金1000萬元,加價幅度40萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.